CORT Jan 2023 15.000 put
| Previous close | 2.2500 |
| Open | 2.2500 |
| Bid | 1.7000 |
| Ask | 5.0000 |
| Strike | 15.00 |
| Expiry date | 2023-01-20 |
| Day's range | 2.2500 - 2.2500 |
| Contract range | N/A |
| Volume | |
| Open interest | 4 |
- Zacks
ProPhase Labs, Inc. (PRPH) Surges 7.6%: Is This an Indication of Further Gains?
ProPhase Labs, Inc. (PRPH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
- Simply Wall St.
Is Corcept Therapeutics Incorporated (NASDAQ:CORT) Popular Amongst Insiders?
The big shareholder groups in Corcept Therapeutics Incorporated ( NASDAQ:CORT ) have power over the company...
- GlobeNewswire
Corcept Therapeutics to Start Phase 3 Trial of Relacorilant Plus Nab-Paclitaxel in Patients With Platinum-Resistant Ovarian Cancer
Positive results of preceding Phase 2 trial to be featured in oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting Figure 1 Figure 1 MENLO PARK, Calif., June 06, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hormone cortisol, today announced that,
